What Ring Therapeutics does

Ring Therapeutics is a privately held, pre-clinical gene therapy company founded in 2017 by Flagship Pioneering and headquartered in Cambridge, Massachusetts. The company is developing the Anellogy platform, which leverages commensal anelloviruses—viruses that have co-evolved with humans for millions of years—as a basis for programmable genetic medicines. Ring has sequenced and characterized over 5,000 anelloviruses, building what is described as the world's first and only anellovirus database, and has developed multiple technology layers including Anellovectors (gene delivery vectors), Vector Conjugates (drug and oligonucleotide delivery), and the VectorBricks/AnelloBricks in vitro modular manufacturing platform, supported by the SATURN packaging system.

The platform targets key limitations of current adeno-associated virus (AAV)-based gene therapies, including inability to redose due to neutralizing antibodies (present in approximately half of patients), limited tissue tropism, and constrained payload capacity. Ring's Anellovectors claim advantages including redosability, immune evasion, expanded payload capacity (up to 65% beyond wild-type genome capacity), and demonstrated 12-month durable expression in vivo. The company has prioritized ophthalmology and oncology as lead therapeutic areas, with additional pipeline breadth across CNS, hematology, metabolic, and inflammatory diseases. Strategic partnerships with A*STAR and SERI in Singapore (November 2024) extend the company's R&D footprint internationally.

Ring Therapeutics is pre-revenue with no commercial products and does not publicly disclose financial figures. The company has raised $230 million cumulatively from Flagship Pioneering and institutional investors including Invus, T. Rowe Price, Alexandria Venture Investments, Kyowa Kirin, and UPMC Enterprises. Its business model contemplates future revenue from therapeutic product commercialization, platform licensing and co-development arrangements with pharmaceutical partners, and research collaborations. The company is led by CEO Christopher McNulty (appointed December 2024), with a leadership team drawn from Biogen, Genzyme/Sanofi, Codiak BioSciences, Intellia Therapeutics, and Ionis Pharmaceuticals. As of 2025, Ring is advancing toward IND filing with Vector Conjugate and VectorBricks capabilities being presented at ASGCT 2026.

Name

Ring Therapeutics

Legal name

Ring Therapeutics, Inc.

Website

https://ringtx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Ring Therapeutics is a pre-clinical gene therapy company developing the Anellogy platform of anellovirus-based vectors for redosable, immune-evading delivery of genetic medicines targeting genetic disorders, ophthalmology, and oncology.

Ownership category

akta.pro rank

Product category

Gene Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI)

akta.pro secondary industry

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Gene therapy platforms
• Viral vector development
• Biopharmaceutical therapeutics
• Anellovirus-based vectors
• Programmable genetic medicines

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Therapeutic Development and Commercialization: Ring Therapeutics is developing a pipeline of Anellovector-based therapeutics targeting genetic disorders, ophthalmology, oncology, and other diseases. As a pre-clinical stage company, revenue will come from commercializing therapeutic products developed on its Anellogy platform once they receive regulatory approval.
2. Platform Licensing and Partnerships: The company may generate revenue through licensing its Anellogy platform technology to pharmaceutical and biotechnology partners for co-development of therapeutics, as well as through strategic partnerships that include upfront payments, milestone payments, and royalties on product sales.
3. Research Collaborations: Strategic research partnerships with academic institutions and research organizations (such as A*STAR and SERI) that may include funding, co-development agreements, and shared intellectual property rights.

Go-to-market motion2 records

Marketing channels5 records

Core offering

Ring Therapeutics develops programmable genetic medicines through its proprietary Anellogy platform, which engineers redosable viral vectors from commensal human anelloviruses. The company creates Anellovectors (gene delivery vectors), Vector Conjugates (drug delivery conjugates including VDCs and VOCs), and a VectorBricks modular manufacturing platform. Therapeutic focus areas include ophthalmology, oncology, CNS disorders, hematology, and metabolic diseases.

Product overview

Ring Therapeutics has developed a comprehensive platform for programmable genetic medicines based on human commensal anelloviruses. The core Anellogy Platform enables the creation of Anellovector viral vectors that leverage the unique properties of anelloviruses—diversity, immune evasion, and tissue tropism—to overcome key limitations in gene therapy. The company has expanded its technology through the Vector Conjugate Platform, which includes Vector Drug Conjugates (VDCs) for small molecules and Vector Oligonucleotide Conjugates (VOCs) for siRNA/antisense delivery. Manufacturing is enabled by the VectorBricks/AnelloBricks in vitro assembly platform, a modular system that dramatically reduces production complexity and cost. The SATURN system enables vector packaging across diverse anellovirus capsids, while Anelloscope and AnelloScan support research and characterization of the anellovirus virome.

Differentiator

Problem solved

Functional benefit

Brands

• Anellogy: The company's platform technology for developing programmable genetic medicines using commensal anelloviruses as vectors for gene therapy.
• Vectorology
• VectorBricks
• AnelloBricks
• Anellovector
• Vector Conjugate
• Vector Oligonucleotide Conjugates (VOCs)
• Vector Drug Conjugates (VDCs)

Products and services

• Anellogy Platform A proprietary gene therapy platform based on commensal human anelloviruses that enables tissue-specific delivery, redosability, and immune evasion for the development of programmable genetic medicines. Offered to pharmaceutical and biotech partners for co-development and licensing.
• Anellovector Viral vectors derived from human commensal anelloviruses engineered to deliver DNA payloads to target cells and tissues with potential for repeated dosing, immune evasion, and high payload capacity. The core product underlying Ring's gene therapy development pipeline.
• Vector Conjugate Platform Platform technology that combines Anellovectors with targeting moieties to expand payload capacity and improve cell and tissue targeting for diverse therapeutic modalities including small molecules and oligonucleotides. Enables Vector Drug Conjugates (VDCs) and Vector Oligonucleotide Conjugates (VOCs).
• VectorBricks (AnelloBricks) Manufacturing Platform A modular, cell-free in vitro assembly manufacturing platform enabling scalable, low-cost production of vector conjugate medicines through assembly of recombinant capsid proteins and nucleic acid payloads, simplifying production to the level of recombinant protein manufacturing.

Quantifiable outcome

• Packaging capacity up to 5.0kb, representing 65% beyond wild-type genome capacity
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• A*STAR (Agency for Science, Technology and Research)coreStrategic or Co-development Partner · 4 November 2024Strategic R&D partnership with Singapore's lead public sector R&D agency to accelerate development of novel therapeutic candidates in ophthalmology and oncology. The partnership includes characterization of novel anellovirus genomes, testing of novel payloads across multiple therapeutic areas, and enhancement of bioprocessing technologies for next-generation manufacturing.
• SERI (Singapore Eye Research Institute)coreStrategic or Co-development Partner · 4 November 2024Strategic partnership with Singapore's national research institute for ophthalmic and vision research to advance gene therapy R&D for eye diseases. The collaboration aims to develop Ring's novel class of viral vectors with higher tropism and redosability for treatment of ophthalmic diseases that previously had no effective treatments.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Tessera Therapeutics: Sibling Flagship Pioneering company developing Gene Writing therapeutics — a different novel gene medicine modality (programmable DNA writing vs. anellovirus-based vectors) at a similar pre-clinical/early-clinical stage. Most direct structural comparable given shared parent, shared investor base, and overlapping gene therapy platform ambitions.
• Generation Bio: Pre-clinical/early-clinical developer of non-viral gene therapy using LNP delivery (ceDNA platform). Pursues the same redosability and immune-evasion thesis as Ring but via a non-viral modality, making it the closest modality-substitute peer for redosable gene therapy programs.
• Voyager Therapeutics: Clinical-stage AAV gene therapy company developing CNS-targeted treatments, including engineering approaches to address AAV limitations (tropism, dosing). A direct AAV-vector competitor to Ring with similar neurology indications but using the incumbent vector class Ring is positioning to disrupt.
• Verve Therapeutics: Clinical-stage in vivo gene editing company using base editing to treat cardiovascular disease. Pursues one-time, in vivo genetic medicines — a competing paradigm to Ring's redosable gene therapy approach for chronic systemic indications.
• Intellia Therapeutics: Clinical-stage CRISPR/Cas9 gene editing company developing in vivo and ex vivo therapies, including with partner Regeneron. Competes with Ring for the same chronic systemic genetic disease markets using a different disruptive modality (gene editing vs. anellovirus vectors).
• Beam Therapeutics: Clinical-stage base editing company with in vivo and ex vivo programs across multiple indications including sickle cell disease and certain ophthalmology targets. Competes directly with Ring in redosable/curative genetic medicine using an alternative platform.

Broad incumbents

• Regenxbio: Commercial-stage AAV gene therapy platform company with approved product (ABECMA via partner) and broad pipeline in ophthalmology, CNS, and metabolic disease. Represents the incumbent AAV-based paradigm Ring is positioning to displace with its anellovirus platform.
• BioMarin Pharmaceutical: Large commercial-stage biotech with multiple approved gene therapies (Roctavian for hemophilia A). Operates across a wide portfolio of rare disease products including gene therapy, serving as a reference point for what commercial gene therapy success looks like at scale.
• uniQure: Clinical/commercial-stage AAV gene therapy company with approved product (Hemgenix for hemophilia B) and pipeline in CNS and other indications. Represents an established AAV incumbent with real-world gene therapy commercialization experience that Ring's eventual commercialization must compete against.

Emerging players

• 4D Molecular Therapeutics: Clinical-stage gene therapy company using evolved and computationally designed AAV capsids to overcome tissue tropism and immune limitations — pursuing the same thesis as Ring (better vectors for genetic medicine) via a different novel vector engineering approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ring_tx
• LinkedInlinkedin.com/company/ring-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ring Therapeutics